Clinical Trial Update: 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This update reports Phase 2 results for the diagnostic imaging agent 68Ga-PSMA-11 PET in diagnosing metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: Thomas Hope | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-16